Eledon Pharmaceuticals Inc
ELDN3.365USD
-0.015-0.44%
交易中 （美東）報價延遲15分鐘
201.50M總市值
7.21本益比TTM
關於 Eledon Pharmaceuticals Inc 公司
Eledon Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司正在開發用於管理和治療危及生命的疾病的免疫調節療法。該公司的主要研究產品是 tegoprubart，這是一種對 CD40 配體具有高親和力的抗 CD40L 抗體，CD40 配體是共刺激 CD40/CD40L 細胞通路中經過充分驗證的生物靶點。CD40L 信號在適應性和先天性免疫細胞活化和功能中的核心作用使其成爲非淋巴細胞耗竭、免疫調節治療干預的有吸引力的靶點。Tegoprubart 的設計旨在潛在地提高安全性並提供藥代動力學、藥效學和劑量優勢。CD40L 主要在活化的 CD4+ T 細胞、血小板和內皮細胞上表達，而 CD40 受體則在抗原呈遞細胞（如巨噬細胞和樹突狀細胞）以及 B 細胞上組成性表達。
公司簡介
公司代碼ELDN
公司名稱Eledon Pharmaceuticals Inc
上市日期Sep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
員工數量31
證券類型Ordinary Share
年結日Sep 17
公司地址19800 Macarthur Blvd.
城市IRVINE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編92612
電話19492388090
網址https://eledon.com/
公司代碼ELDN
上市日期Sep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月4日 週五
更新時間: 7月4日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
持股股東
持股股東
佔比
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
股東類型
持股股東
佔比
Hedge Fund
28.61%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
10.61%
Venture Capital
5.96%
Corporation
1.36%
Research Firm
1.17%
Pension Fund
0.12%
Family Office
0.07%
Individual Investor
0.03%
Other
34.87%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
126
38.97M
65.08%
-2.26M
2025Q1
124
39.32M
65.66%
-3.87M
2024Q4
105
38.47M
64.39%
+11.26M
2024Q3
70
19.89M
51.00%
-1.66M
2024Q2
71
20.04M
55.99%
+4.61M
2024Q1
65
11.37M
47.26%
-1.53M
2023Q4
63
10.93M
50.76%
-2.06M
2023Q3
65
10.70M
50.83%
-4.12M
2023Q2
66
11.20M
53.85%
+179.31K
2023Q1
67
8.42M
61.13%
-3.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
6.29M
10.51%
--
--
Mar 31, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.95M
4.93%
+58.49K
+2.02%
Mar 31, 2025
First Light Asset Management, LLC
2.33M
3.89%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
2.31M
3.85%
-244.50K
-9.58%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.82M
3.04%
-140.00K
-7.14%
Mar 31, 2025
Woodline Partners LP
1.67M
2.79%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.59M
2.65%
+1.32M
+489.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.32M
2.2%
-196.91K
-12.99%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.26M
2.11%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Inspire Fidelis Multi Factor ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.04%
Global X Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
ALPS Medical Breakthroughs ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Inspire Fidelis Multi Factor ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
公告日期
類型
比率
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
